Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10434175 Agonist antibodies that bind human CD137 and uses thereof

Patent 10434175 was granted and assigned to Compass Therapeutics Llc on October, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Robert V. Tighe, III0

Ugur Eskiocak0

Cheuk Lun Leung0

Jason M. Lajoie0

Michael March Schmidt0

Paul Widboom0

Piotr Bobrowicz0

Date of Patent

October 8, 2019

0

Patent Application Number

164205110

Date Filed

May 23, 2019

0

Patent Citations

US Patent 10279039 Agonist antibodies that bind human CD137 and uses thereof

US Patent 10279038 Agonist antibodies that bind human CD137 and uses thereof

US Patent 10279040 Agonist antibodies that bind human CD137 and uses thereof

0

Patent Citations Received

US Patent 11851497 CD137 antibodies and tumor antigen-targeting antibodies and uses thereof

0

US Patent 11752207 Agonist antibodies that bind human CD137 and uses thereof

Patent Primary Examiner

0

Patent abstract

The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10434175 Agonist antibodies that bind human CD137 and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool